Abstract
Introduction: NiFe2O4@SiO2nPr@glucose catalyzed synthesis of novel 5-pyrazolin-1,2,4-triazazolidine- 3-ones (thiones).
Materials and Methods: Amino glucose-functionalized silica-coated NiFe2O4 nanoparticles (NiFe2O4@SiO2 nPr@glucose amine or NiFe2O4@SiP@GA) were synthesized and characterized by X-ray powder diffraction (XRD), X-ray spectroscopy (EDX), transmission electron microscope (TEM), field emission scanning electron microscope (FE-SEM), vibrating sample magnetometry (VSM) and fourier transform infrared spectroscopy (FTIR).
Results and Discussion: NiFe2O4@SiP@GA supply an eco-friendly procedure for the synthesis of some novel 5- pyrazolin-1,2,4-triazazolidine-3-ones or thiones through one-pot reaction of thiosemicarbazide (hydrazinecarbothioamide) and synthetized pyrazole carbaldehydes. These compounds were obtained in high yields in short reaction times. The catalyst could be easily recovered and reused for six cycles with almost consistent activity. The structures of the synthesized 5-pyrazolin-1,2,4-triazazolidine-3-ones or thiones were confirmed by 1H NMR, 13C NMR and FTIR spectral data and elemental analyses.
Conclusion: In conclusion, we have investigated NiFe2O4@SiO2nPr@amino glucose as a new, eco-friendly, inexpensive, mild and reusable catalyst for the synthesis of 5-pyrazolin-1,2,4-triazazolidine-3-ones or thiones. High yield, a simple workup procedure, adherence to the basics of green chemistry, environmental friendly and based on natural ingredients, ease of separation and recyclability of the magnetic catalyst and waste reduction are some advantages of this method.
Keywords: Nanocatalyst, 5-pyrazolin-1, 2, 4-triazazolidine-3-ones, NiFe2O4, thiosemicarbazide, aldehyde, triazazolidine-3-thiones.
Graphical Abstract
[http://dx.doi.org/10.3762/bjoc.9.265 PMID: 24204439]
[http://dx.doi.org/10.2174/1568026616666160506145539 PMID: 27150367]
[http://dx.doi.org/10.1039/C6RA02953A]
[http://dx.doi.org/10.1016/j.tetlet.2005.02.167]
[http://dx.doi.org/10.1002/ejoc.200500247]
[http://dx.doi.org/10.1021/ja905056z PMID: 19799379]
[http://dx.doi.org/10.1021/ol902207h PMID: 19943701]
[http://dx.doi.org/10.1016/S0022-1139(00)00287-6]
[http://dx.doi.org/10.1023/A:1013275515682]
[http://dx.doi.org/10.1016/j.farmac.2003.11.002 PMID: 15081342]
[http://dx.doi.org/10.1002/jhet.5570210460]
[http://dx.doi.org/10.1002/jccs.200000046]
[PMID: 9540106]
[http://dx.doi.org/10.3390/90400204 PMID: 18007424]
[http://dx.doi.org/10.1002/jhet.5570210624]
[http://dx.doi.org/10.1016/S0014-827X(98)00074-3 PMID: 10081823]
[http://dx.doi.org/10.1016/S0223-5234(03)00148-X PMID: 14561484]
[http://dx.doi.org/10.1002/jhet.5570360315]
[http://dx.doi.org/10.2174/1570178614666170126154256]
[http://dx.doi.org/10.1007/s10971-017-4310-6]
[http://dx.doi.org/10.1039/b921171c]
[http://dx.doi.org/10.1039/c1cs15079k PMID: 21804997]
[http://dx.doi.org/10.1039/C8RA02572J]
[http://dx.doi.org/10.1016/j.dyepig.2019.107936]
[http://dx.doi.org/10.2174/1570179411666141101001949]
[http://dx.doi.org/10.2174/1386207320666170425123248 PMID: 28443502]